What Technical Analysis say About Halozyme Therapeutics, Inc. (NASDAQ:HALO)?

69

Technical Indicators and Signals

The stochastic oscillator indicator is the important indicator to compare the security price over a certain period of time. The stochastic %K of Halozyme Therapeutics, Inc. (NASDAQ:HALO) for the period of 9-Day stands at 74.37% while the stochastic %D for the same period stands at 63.98%.

The 7-Day Average Directional Index ADX (also known as Trend Strength Indicator) of Halozyme Therapeutics, Inc. (NASDAQ:HALO) signals “Buy” while other important signals like the 20-Day Moving Average Vs. Price signals “Buy”.

Another important signal of trend and momentum of a security is 20-50 Day MACD Oscillator or Moving Average Convergence Divergence signals “Buy” for Halozyme Therapeutics, Inc. (NASDAQ:HALO) while 20-100 Day MACD Oscillator indicates “Buy”.

Bollinger band is a volatility indicator of a certain security, currently Halozyme Therapeutics, Inc. (NASDAQ:HALO)’s 20-Day Bollinger Band indicates “Hold”.

About Company

Halozyme Therapeutics, Inc. is a therapeutically driven, development stage biopharmaceutical company dedicated to developing and commercializing recombinant human enzymes for the infertility, ophthalmology, and oncology communities. The company’s broad product development portfolio, including expected near- and long-term product offerings, is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company’s initial products are being developed to offer safer and purer alternatives toexisting slaughterhouse derived extracts that carry risks of pathogen contamination, immunogenicity, and toxicity. The commercialization of Halozyme’s highly versatile enzyme technology within proven markets will enable the company to positively impact the quality of medicine.

Previous Day Activity Analysis

On the last trading day, Halozyme Therapeutics, Inc. (NASDAQ:HALO) opened the session at $17.52 and after going up 2.23% closed at $17.86. The stock gained 0.34 points in the last trade.

Halozyme Therapeutics, Inc. (NASDAQ:HALO)’s stock fluctuated in the range of $17.52 and $18.43 during the previous active session. Halozyme Therapeutics, Inc. (NASDAQ:HALO) traded with the volume of 1.58 Million with average volume of 1.24 Million. The stock has MEDIUM volatility on the last trading session.

Currently the Beta for the company remains at 2.09 while ATR (Average True Range) and RSI (Relative Strength Index) are at 0.65 and 70.91 respectively.

Currently the Insider Ownership of the shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) is at 3% and the shares outstanding are 144.44 Million.

Important Ratio Analysis

Some important ratios to consider here for Halozyme Therapeutics, Inc. (NASDAQ:HALO) are discussed below:

Dividend yield of Halozyme Therapeutics, Inc. (NASDAQ:HALO) stands at 0% whereas Price to Earnings P/E ratio stands at 0 while Forward P/E shows the value of 0.

The Price to Sale P/S and Price to Book P/B shows the value of 19.22 and 41.53 respectively. While Price to Cash P/C and Price to Free Cash Flow P/FCF stands at 8.67 and 0 correspondingly.

The Quick Ratio of Halozyme Therapeutics, Inc. (NASDAQ:HALO) stands at 3.9 while the Current Ratio depicts the value of 4.1.

Return on Assets ROA of Halozyme Therapeutics, Inc. (NASDAQ:HALO) is at -43% whereas, Return on Equity ROE and Return of Investment ROI of Halozyme Therapeutics, Inc. (NASDAQ:HALO) stand at 0% and -45.8% respectively.

Stock Performance Analysis

The stock performance of Halozyme Therapeutics, Inc. (NASDAQ:HALO) on the basis of 5 day trade show the jump of 6.63% whereas, the monthly performance of the stock shows increase of 9.91%.

The quarterly performance of the stock remained in green zone with the value of 37.7% while six month performance of the shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) remained bullish with the count of 40.3%.

The yearly and YTD performance of Halozyme Therapeutics, Inc. (NASDAQ:HALO) remained up at 77.53% and 80.77% respectively.